JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...
JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
JMP Securities Raises Axon Enterprise, Inc. (AXON) Price Target to $725 on AI & Defense Demand
We recently compiled a list of the 8 AI Stocks on Investors’ Radar. In this article, we are going to take a look at where ...